By Veyvora Research · Updated August 2026
Somatropin (rhGH) Research: Identity and Mechanistic Context
Overview
Somatropin is the World Health Organisation (WHO) international nonproprietary name for recombinant human growth hormone (rhGH), a 191-amino-acid single-chain polypeptide with two disulphide bridges and a molecular mass of approximately 22.1 kDa, matching the principal 22 kDa isoform produced by the human pituitary gland [1]. Produced by recombinant DNA technology, somatropin is not a pituitary extract, not a growth-hormone secretagogue, and not somatrem (N-methionyl-GH), which is a distinct historical analogue [1]. The European Pharmacopoeia and British Pharmacopoeia (BP) somatropin monographs define the identity, purity and assay requirements that characterise a somatropin material.
This article covers three things: how somatropin’s pharmacopoeial identity is established and verified; how its receptor-level mechanism differs from that of secretagogues such as sermorelin, ipamorelin and ibutamoren; and what analytical documentation a research batch carries.
Key Takeaways
- Somatropin identity is confirmed by orthogonal physicochemical methods, peptide mapping, RP-HPLC and mass spectrometry, read together rather than from a single immunoassay result.
- Somatropin acts directly on the growth-hormone receptor (GHR); secretagogues act upstream on pituitary somatotrophs, so a GHR-binding or JAK2-STAT5 pathway assay uses somatropin itself.
- Somatropin is also the active substance of registered medicines such as Omnitrope; the research material is a separate laboratory presentation, documented by its batch certificate against the pharmacopoeial monograph.
| Attribute | Detail |
|---|---|
| Price | See the live product page |
| UK availability | See the live product page |
| Dispatch | 24-hour dispatch stated by Veyvora |
| Batch documentation | Batch-specific certificate of analysis supplied |
| Purchase or enquiry path | Direct via Veyvora |
For laboratory researchers, the starting point for any somatropin batch is identity verification against the pharmacopoeial standard.
Definition and Identity
Identity is defined by the authentic mature GH1 sequence, correct disulphide pairing and the expected monomer mass. The European Pharmacopoeia and BP somatropin monographs, together with Medicines and Healthcare products Regulatory Agency (MHRA)- and European Medicines Agency (EMA)-authorised product information, set the pharmacopoeial identity standard against which any research batch should be assessed [1]. A supplier’s stated purity percentage is one line of that assessment; understanding how HPLC purity works clarifies what chromatographic data establishes.
Researchers sourcing somatropin for in-vitro use should verify a batch against its certificate of analysis (CoA) before use, confirming that the certificate references the correct sequence identity, molecular mass and analytical method.
Mechanism and Research Context
In in-vitro settings, somatropin functions as a direct ligand for the growth-hormone receptor (GHR), a class I cytokine receptor expressed on target cells. Binding drives receptor homodimerisation, which activates the associated Janus kinase 2 (JAK2) and initiates phosphorylation of signal transducer and activator of transcription 5 (STAT5), the cause-and-effect chain that makes somatropin the appropriate material for direct GHR-binding assays. Secondary signalling branches through the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathways also engage downstream of GHR activation [1].
How Direct GH Supply Differs from Secretagogue Action
This receptor-level mechanism is the critical distinction between somatropin and growth-hormone secretagogues. Secretagogues, including growth-hormone-releasing hormone (GHRH)-receptor agonists such as sermorelin and tesamorelin, and ghrelin/GHS-R1a agonists such as ipamorelin, GHRP-2 and ibutamoren, act upstream on pituitary somatotrophs to stimulate endogenous GH release, rather than supplying the 191-residue GH ligand directly. Because secretagogues are not the GH ligand, somatropin is the material for a GHR-binding or JAK2-STAT5 pathway assay. A researcher designing a GHR-ligand study uses somatropin to engage the receptor directly.
IU as an Analytical Presentation Unit
International Units (IU) on a somatropin CoA represent biological activity expressed relative to a WHO International Standard, not a protocol quantity or experimental dose. Recombinant quantity is separately reported in milligrams by physicochemical assay. These are two distinct measurement frameworks; this article does not convert IU into experimental doses or treatment regimens.
Correct cold-chain handling preserves the structural integrity that underpins GHR binding; Veyvora’s storage and stability guidance covers the temperature and reconstitution conditions relevant to research batches. Researchers ready to review available formats can browse the somatropin research pen or the broader Growth & Recovery research pens category after confirming identity and verification requirements.
What the Evidence Shows
Authoritative identity and quality evidence for somatropin as a defined research substance is pharmacopoeial and regulatory in origin.
Pharmacopoeial and Regulatory Standards
The European Pharmacopoeia and BP somatropin monographs set the analytical framework for identity confirmation: required tests include peptide mapping, related-protein determination, dimer and higher-molecular-mass related-substance quantification, host-cell-derived protein assays, and a physicochemical quantity assay. These monographs specify numerical acceptance limits as printed in the current edition. The EMA’s European Public Assessment Report (EPAR) for Omnitrope documents the recombinant production system and quality module for that registered product [1], and the EPAR is a reference for what a pharmacopoeial-grade characterisation looks like.
WHO International Standards and Biological Activity
WHO International Standards exist so that biological activity can be expressed relative to a named reference preparation, an analytical convention, not a protocol quantity [1]. The National Institute for Biological Standards and Control (NIBSC) holds the relevant somatropin International Standard; IU values on a CoA are meaningful only when the assay method and reference preparation are both stated.
Mechanistic Evidence
Primary GHR-JAK2-STAT5 receptor biology papers establish the ligand mechanism that makes somatropin the appropriate material for direct GHR-binding assays [1]. Researchers who need the adjacent secretagogue mechanism, where upstream pituitary stimulation replaces direct GH supply, can review the CJC-1295 and ipamorelin secretagogue profile or the tesamorelin GHRH analogue profile for the contrasting pathway without conflating it with somatropin’s receptor-level action.
State of the Evidence
Analytical Methods
Immunoassay can cross-react with structurally related proteins, so identity is confirmed by orthogonal physicochemical methods. Peptide mapping, reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry each address different aspects of identity and purity and are read together. The how HPLC purity works page clarifies what a chromatographic purity figure establishes about sequence identity and aggregate content.
Batch and Process Specificity
Host-cell impurity profiles depend on the expression system, for example E. coli versus mammalian cell lines, and are batch- and process-specific, so each lot is characterised by its own result. A supplier’s stated specification documents that supplier’s acceptance criteria; the batch certificate reports the measured values. To match a physical batch against its documentation, verify a batch against its CoA using the named method, reference standard and reportable result.
Comparison with Related Entities
Somatropin is the 191-residue recombinant human GH ligand and is not interchangeable with any compound that acts upstream to stimulate endogenous GH release, nor with structurally distinct GH variants or related peptides.
Secretagogues
Secretagogues, including GHRH analogues such as sermorelin and tesamorelin, and ghrelin-receptor agonists such as growth-hormone-releasing peptide-2 (GHRP-2), GHRP-6, ipamorelin and ibutamoren, act on pituitary somatotrophs rather than supplying the GH ligand directly [2]. Because secretagogues are not somatropin, a GHR-ligand binding or JAK2-STAT5 signalling assay uses somatropin itself.
Other Structurally Distinct Entities
Several further materials are commonly conflated with somatropin but are chemically distinct [2]:
- Somatrem, an N-methionyl analogue; a different historical molecule, not covered by the somatropin monograph.
- IGF-1 (mecasermin), insulin-like growth factor 1, the downstream effector peptide, not the GH ligand.
- 20 kDa GH splice variant, a naturally occurring isoform with a different primary structure.
- Long-acting conjugates, somapacitan, somatrogon and lonapegsomatropin are chemically modified fusion proteins or conjugates outside the somatropin monograph identity.
- Recombinant bovine somatotropin (rBST), a different species sequence; its use in dairy production is not authorised in the UK or EU.
- Pituitary-derived human GH, a historical source class withdrawn from licensed supply owing to prion risk; pituitary-derived material is not a current equivalent.
Researchers sourcing material for GHR-pathway studies should confirm that the batch CoA identifies the 191-residue sequence specifically, rather than a related protein.
Material Identity and Analytical Context
Confirming somatropin identity requires orthogonal physicochemical methods. The European Pharmacopoeia and BP somatropin monographs specify identification by peptide mapping, RP-HPLC and mass spectrometry, alongside tests for related proteins, dimers, higher-molecular-mass substances and host-cell-derived impurities [1]. An immunoassay can cross-react with structurally related proteins and does not establish sequence identity; immunoassay supplements, rather than replaces, chromatographic and spectrometric confirmation.
Reading the Certificate of Analysis
A batch-specific CoA names the analytical method, the reference standard used (such as a European Directorate for the Quality of Medicines (EDQM) chemical reference substance or a WHO/NIBSC International Standard for biological activity), and provides a reportable chromatogram or spectrum. The purity percentage reports chromatographic purity; sequence identity, aggregate content and host-cell impurity levels are reported by the peptide map, the related-substance tests and the host-cell protein assay respectively [1].
IU on a CoA represents biological activity referenced to a WHO International Standard; IU is an analytical presentation unit, not a protocol quantity. Recombinant content is reported in milligrams by physicochemical assay.
Research Use
Somatropin research material is supplied for in-vitro laboratory work: GHR-binding assays, JAK2-STAT5 pathway studies and use as an analytical reference against the pharmacopoeial monograph. Not for human or veterinary use. Somatropin is also the active substance of registered prescription medicines such as Omnitrope [1]; the research material is a separate laboratory presentation, documented by its batch certificate.
The scope of this article is in-vitro laboratory identity and mechanism.
Sources
[1] Omnitrope | European Medicines Agency (EMA), ema.europa.eu, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope [2] The Safety and Efficacy of Growth Hormone Secretagogues, Sigalos & Pastuszak, Sexual Medicine Reviews (PMC5632578), pmc.ncbi.nlm.nih.gov, 2017, https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/
